Brown Advisory Inc Annovis Bio, Inc. Transaction History

Brown Advisory Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$30.95 - $120.97 $140,574 - $549,445	-4,542 Closed	0 $0
Q2 2021 Jul 29, 2021	SELL	$21.55 - $96.1 $62,495 - $278,690	-2,900 Reduced 38.97%	4,542 $389,000
Q1 2021 May 14, 2021	SELL	$8.15 - $38.44 $61,125 - $288,300	-7,500 Reduced 50.19%	7,442 $208,000
Q3 2020 Nov 16, 2020	BUY	$3.84 - $6.78 $57,377 - $101,306	14,942 New	14,942 $72,000

1.16M

229K

934K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $54.5M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.